Study on the pathogenic progression from transient myeloproliferative disorder to acute megakaryoblasticm leukemia in Down syndrome using DNA microarrays

利用DNA微阵列研究唐氏综合症从短暂性骨髓增生性疾病到急性巨核细胞白血病的致病进展

• 批准号: 16591021
• 负责人: KAMACHI Yoshiro
• 金额: $ 2.18万
• 依托单位: Nagoya University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16591021/
• 关键词: DNA Microarrays; Down syndrome; Transient Myeloproliferative disorder; Acute Megakaryoblastic leukemia

Approximately 10% of newborns with Down syndrome develop transient myeloproliferative disorder (TMD), a disorder that is unique to infants with constitutional trisomy 21 or trisomy 21 mosaicism. TMD blasts disappear spontaneously within the first 3 months of life in the majority of cases. Despite the resolution of TMD, 20-30% of these newborns will go on to develop acute megakaryoblastic leukemia (AMKL) within the 3 years. In this study, samples from both TMD and AMKL patients were examined using DNA microarrays to study the pathogenic progression from TMD to AMKL. Because we were able to obtain only three high-quality mRNA from each patient group respectively, we could not find different gene expression pattern between two groups. In order to identify genes contributing to develop AMKL from TMD in DS patients using DNA microarrays, we have to increase available number of cases in future. Further studies are needed to identify genes contributing to develop AMKL from TMD in DS patients.

大约10%的唐氏综合征新生儿发展为一过性骨髓增生性疾病（TMD），这是一种先天性21三体或21三体嵌合体婴儿所特有的疾病。在大多数情况下，TMD胚细胞在出生后的前3个月内自发消失。尽管TMD的决议，20-30%的新生儿将继续发展急性巨核细胞白血病（AMKL）在3年内。在这项研究中，从TMD和AMKL患者的样本进行了检查，使用DNA微阵列来研究从TMD到AMKL的致病进展。由于我们只能从每个患者组中分别获得三种高质量的mRNA，因此我们无法发现两组之间不同的基因表达模式。为了使用DNA微阵列鉴定有助于DS患者从TMD发展AMKL的基因，我们必须在未来增加可用的病例数。需要进一步的研究来鉴定有助于DS患者TMD发展为AMKL的基因。

项目成果

Engraftment of NOD/SCID/γ mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukemia.

将来自幼年粒单核细胞白血病患者的多系肿瘤细胞移植到 NOD/SCID/γ 小鼠中。

• 发表时间: 2005
• 期刊: Br J Haematol. 130(1)
• 作者: Nakamura Y;Kamachi Y;et al.
• 通讯作者: et al.

Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale : a simple culture system using tetrameric HLA-peptide complexes.

将人 CMV 特异性细胞毒性 T 淋巴细胞扩展到临床规模：使用四聚体 HLA-肽复合物的简单培养系统。

• 发表时间: 2004
• 期刊: Cytotherapy. 6
• 作者: Watanabe N;Kojima S;et al.
• 通讯作者: et al.